Natera, Inc. (NASDAQ:NTRA) Chief Financial Officer Michael Burkes has sold shares of the company's stock, according to recent filings with the Securities and Exchange Commission. The transactions, which occurred over a span of three days, resulted in a total sale value exceeding $219,000.
The sales were made at prices ranging from $89.55 to $92.9991 per share. On April 24, Burkes sold 937 shares at approximately $92.9991 each. The following day, an additional 705 shares were sold at a price of $89.55 per share. The transactions continued on April 26, with 751 shares sold at $92 per share.
Following these transactions, the filings indicated that Burkes still owns a substantial number of shares in the company. Investors often monitor insider sales as they may provide insights into an executive's view of the company's current valuation and future prospects.
The sales reported were executed in accordance with a Rule 10b5-1 trading plan, which was adopted by Burkes on March 14, 2023. Such plans allow company insiders to establish pre-planned transactions to sell a predetermined number of shares at a specified time, providing a defense against potential accusations of insider trading.
These recent sales by a high-ranking Natera executive may attract the attention of investors seeking to interpret the actions of company insiders. Natera, Inc., headquartered in Austin, Texas, specializes in genetic testing and diagnostics, offering services in areas such as prenatal screening and cancer detection.
InvestingPro Insights
As Natera, Inc. (NASDAQ:NTRA) navigates through a period where insider transactions are closely scrutinized, the company's financial metrics and market performance provide a broader context for investors. Despite the insider sales, Natera's recent market activity shows a significant uptick, with a 40.07% price total return over the last three months and an impressive 139.57% over the last six months, reflecting strong investor confidence.
InvestingPro data highlights the company's robust revenue growth, with the last twelve months as of Q4 2023 showing a 31.99% increase in revenue, indicating Natera's expanding market presence in the genetic testing sector. However, it's important to note that the company is currently not profitable, with a negative P/E ratio of -24.25 and an adjusted P/E ratio for the same period at -25.77.
Two InvestingPro Tips for Natera include the company's high return over the last year and its strong return over the last three months. These metrics suggest that, despite not being profitable over the last twelve months, the company's stock has provided substantial returns to investors who held shares during these periods. Additionally, Natera's liquid assets exceed its short-term obligations, which may offer some reassurance regarding the company's financial stability.
For investors seeking a deeper dive into Natera's performance and potential, InvestingPro offers a wealth of additional insights. With a range of InvestingPro Tips available, users can gain a more comprehensive understanding of the company's financial health and market position. To access these insights and more, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.